Nateghi Saeed, Gomari Mohammad Mahmoudi, Roudsari Yousef Jalali, Foroughi Alireza, Mansouri Fariba, Shiva Ashkan, Nasrollahizadeh Ali, Nasiri Zohreh, Faraji Neda
Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Prim Care Diabetes. 2022 Jun;16(3):361-364. doi: 10.1016/j.pcd.2022.03.005. Epub 2022 Mar 9.
Blood sugar (BS) has been proposed as a prognostic factor for COVID-19. In this historical cohort study we evaluated the association between admission time BS and COVID-19 outcome.
First, hospitalized COVID-19 patients were divided into three groups; Non-diabetic patients with BS < 140 mg/dl (N = 394), non-diabetic patients with BS ≥ 140 mg/dl (N = 113) and diabetic patients (N = 315). Mortality, ICU admission, and length of hospital stay were compared between groups and odds ratio was adjusted using logistic regression.
After adjustment with pre-existing conditions and drugs, it was shown that non-diabetic patients with BS ≥ 140 mg/dl are at increased risk of mortality (aOR 1.89 (0.99-3.57)) and ICU admission (aOR 2.62 (1.49-4.59)) even more than diabetic patients (aOR 1.72 (1.07-2.78) for mortality and aOR 2.28 (1.47-3.54) for ICU admission.
Admission time hyperglycemia predicts worse outcome of COVID-19 and BS ≥ 140 mg/dl is associated with a markedly increase in ICU admission and mortality.
血糖(BS)已被提出作为COVID-19的一个预后因素。在这项历史性队列研究中,我们评估了入院时血糖与COVID-19预后之间的关联。
首先,将住院的COVID-19患者分为三组;血糖<140mg/dl的非糖尿病患者(N = 394)、血糖≥140mg/dl的非糖尿病患者(N = 113)和糖尿病患者(N = 315)。比较各组之间的死亡率、入住重症监护病房(ICU)情况和住院时间,并使用逻辑回归调整比值比。
在对既往疾病和药物进行调整后,结果显示血糖≥140mg/dl的非糖尿病患者的死亡风险(调整后比值比[aOR]为1.89[0.99 - 3.57])和入住ICU的风险(aOR为2.62[1.49 - 4.59])甚至高于糖尿病患者(死亡的aOR为1.72[1.07 - 2.78],入住ICU的aOR为2.28[1.47 - 3.54])。
入院时高血糖预示着COVID-19的预后更差,且血糖≥140mg/dl与入住ICU和死亡率的显著增加相关。